<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rapid overview of initial ICU management of patients with suspected COVID-19 infection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rapid overview of initial ICU management of patients with suspected COVID-19 infection</h1>
<div class="graphic"><div class="figure"><div class="ttl">Rapid overview of initial ICU management of patients with suspected COVID-19 infection</div><div class="cntnt"><table cellspacing="0"><colgroup width="24%"></colgroup><colgroup span="2" width="38%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td colspan="3"><strong>ENHANCED PRECAUTIONS: N95 mask* (or equivalent), gloves, gown, eye protection; disposable stethoscope; airborne infection isolation room for aerosol-generating procedures</strong></td> </tr> <tr> <td class="subtitle1_left">Diagnostic testing</td> <td class="subtitle1_left">Actions</td> <td class="subtitle1_left">Explanatory notes</td> </tr> <tr> <td class="indent1">Nasopharyngeal swab</td> <td> <ul> <li>Perform SARS-CoV-2 (COVID-19) test</li> <li>Test for influenza if prevalent in the community</li> <li>Do <strong>not</strong> obtain viral cultures</li> </ul> </td> <td> <ul> <li>In intubated patients, tracheal aspirates and nonbronchoscopic alveolar lavage ("mini-BAL") are also acceptable.</li> <li>Bronchoscopy is only performed for this indication when upper respiratory samples and mini-BAL are negative.</li> </ul> </td> </tr> <tr> <td class="indent1">Other microbiology</td> <td> <ul> <li>Obtain the following: <ul> <li>Blood cultures, if clinically indicated</li> <li>Sputum culture, if clinically indicated (avoid induced sputum)</li> <li>Urinary antigen for <em>Legionella</em>, <em>Pneumococcus</em>, if clinically indicated</li> </ul> </li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Baseline laboratory testing</td> <td> <ul> <li>Obtain the following:<sup>¶</sup> <ul> <li>CBC with differential counts</li> <li>Urinalysis</li> <li>Chemistry panel including LFTs</li> <li>Troponin and BNP at baseline, and subsequently as indicated</li> <li>Consider biomarkers at baseline and for interval monitoring if indicated: procalcitonin, ferritin, CRP, CPK, D-dimer, triglycerides, fibrinogen, LDH</li> </ul> </li> </ul> </td> <td> <ul> <li>Neutrophilia is uncommon while lymphopenia is common, resulting in a high ratio (&gt;50) of neutrophils:lymphocytes.</li> <li>Elevated LFTs are common.</li> <li>Procalcitonin is often low early in illness.</li> <li>Lymphopenia and elevation of LDH, ferritin, and CRP are associated with disease progression and need for mechanical ventilation.</li> <li>The decision for interval monitoring is institution-specific.</li> </ul> </td> </tr> <tr> <td class="indent1">Imaging</td> <td> <ul> <li>Obtain portable chest radiograph</li> <li>POC ultrasound may provide additional information</li> <li>CT only in patients with an indication that would change management</li> </ul> </td> <td> <ul> <li>Main role of POC ultrasound is to identify other causes of respiratory compromise (eg, pneumothorax, pleural effusion, pericardial effusion, heart failure) or other contributors to hypotensive shock.</li> <li>Characteristic findings on POC ultrasound in COVID-19 pneumonia are nonspecific and include pleural thickening and B lines.</li> </ul> </td> </tr> <tr> <td class="indent1">ECG</td> <td> <ul> <li>Baseline at admission</li> <li>Subsequent ECGs for patients on medications that can prolong QTc or patients with troponin elevation</li> </ul> </td> <td> <ul> <li>Medications that can prolong QTc include (among others): azithromycin, hydroxychloroquine, remdesivir, phenothiazines, quetiapine.</li> </ul> </td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Flexible bronchoscopy</td> <td> <ul> <li>Avoid bronchoscopy to prevent aerosol spread unless indicated for reasons other than diagnosis</li> <li>If necessary, perform in airborne infection isolation room</li> </ul> </td> <td> <ul> <li>Bronchoscopy, should only be performed for the diagnosis of COVID-19 when upper respiratory samples and mini-BAL are negative or when indicated for another reason (eg, infection in an immunosuppressed patient; life-threatening hemoptysis or airway obstruction).</li> </ul> </td> </tr> <tr> <td class="subtitle1_left">Supportive care</td> <td class="subtitle1_left">Actions</td> <td class="subtitle1_left">Explanatory notes</td> </tr> <tr> <td class="indent1" colspan="2">Management is largely supportive with surveillance for common complications including ARDS, acute kidney injury, elevated liver enzymes, and cardiac injury. All coinfections and comorbidities should be managed. Patients should be monitored for prolonged QTc interval and for any drug interactions.</td> <td> </td> </tr> <tr> <td class="indent1">Goals of care</td> <td> <ul> <li>Recommend early discussion and involvement of palliative care team as necessary</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Vascular access</td> <td> <ul> <li>Place central venous catheter if indicated (eg, ventilated patient)</li> <li>Place arterial line if frequent need for ABGs anticipated (eg, ventilated patient with ARDS) or blood pressure monitoring is needed</li> <li>Bundle procedures to minimize exposure; review procedure checklist before entering room</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">IV fluids and nutrition</td> <td> <ul> <li>Conservative approach. Use vasopressors preferentially rather than large volume (&gt;30 mL/kg) IV fluid resuscitation; monitor renal functions.</li> <li>Follow standard ICU protocols for nutritional support</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Nebulizer treatments</td> <td> <ul> <li>Avoid nebulizers whenever possible to prevent aerosol spread</li> <li>Use MDIs for inhaled medications (including patients on mechanical ventilation)</li> <li>When required for some patients with asthma and COPD exacerbation, give nebulizers in an airborne infection isolation room</li> </ul> </td> <td> <ul> <li>If MDIs are not available, the patients may be able to use their own supply.</li> </ul> </td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Oxygen/respiratory support</td> <td> <ul> <li>Goal SpO<sub>2</sub> 88 to 96%</li> <li>May give NC up to 6 L/minute or NRB up to 10 L/minute</li> <li>Use of HFNC preferred over NIV. Each institution should have a policy outlining management approach. <ul> <li>HFNC and NIV increase risk of aerosolization; use surgical mask over HFNC or NIV interfaces</li> <li>NIV may be preferred for indications with known benefit (eg, acute hypercapnia due to COPD exacerbation or ACHF)</li> <li>Reassess patients on HFNC and NIV every 1 to 2 hours, or sooner if SpO<sub>2</sub> &lt;90 or clinical deterioration</li> </ul> </li> </ul> </td> <td> <ul> <li>Some experts advocate placing a surgical mask on patients wearing low-flow oxygen devices, although the efficacy of this approach is unclear. It may be appropriate if the patient is not in an airborne isolation room or during transport.</li> <li>Special attention should be paid to using SpO<sub>2</sub> targets in patients with dark skin tones, given data that report overestimation of SpO<sub>2</sub> and risk of occult hypoxemia in these populations.</li> </ul> </td> </tr> <tr> <td class="subtitle1_left">Tracheal intubation and mechanical ventilation</td> <td class="subtitle1_left">Actions</td> <td class="subtitle1_left">Explanatory notes</td> </tr> <tr> <td class="indent1">Indications</td> <td> <ul> <li>Rapid progression over hours</li> <li>Persistent need for high flows/FiO<sub>2</sub> (eg, &gt;60 L/minute and an FiO<sub>2</sub> &gt;0.6)</li> <li>Evolving hypercapnia, increasing work of breathing, increasing tidal volume, worsening mental status, increasing duration and depth of desaturations</li> <li>Hemodynamic instability or multiorgan failure</li> </ul> </td> <td> <ul> <li>Do <strong>not</strong> delay intubation until the patient has features of impending respiratory arrest (eg, respiratory rate &gt;30/minutes, accessory muscle use, abdominal paradox) or is on maximum noninvasive supportive care since this approach is potentially harmful to both the patient and healthcare workers.</li> </ul> </td> </tr> <tr> <td class="indent1">Rapid sequence intubation</td> <td> <ul> <li>Performed by experienced intubator</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Ventilator settings</td> <td> <ul> <li>Provide low TV ventilation: <ul> <li>AC with TV target 6 mL/kg IBW</li> <li>PEEP/FiO<sub>2</sub>: PEEP 10 to 15 cm H<sub>2</sub>O to start</li> <li>Titrate oxygen to target PaO<sub>2</sub> 55 to 80/SpO<sub>2</sub> 88 to 96 for most patients</li> <li>Plateau pressure &lt;30 cm H<sub>2</sub>O</li> </ul> </li> </ul> </td> <td> <ul> <li>ARDSNet provides a guide to PEEP and FiO<sub>2</sub> titration; refer to UpToDate text for details.</li> </ul> </td> </tr> <tr> <td class="indent1">Prone ventilation</td> <td> <ul> <li>Suggest prone positioning should low TV ventilation fail (eg, P/F ratio <span class="nowrap_whitespace">&lt;150 mmHg × 12 hours,</span> FiO<sub>2</sub> requirement ≥0.6, requirement for PEEP ≥5 cm H<sub>2</sub>O)</li> <li>Advise daily prone position for 12 to 16 hours/day</li> <li>Need experienced staff; ensure that ETT and vascular access remain secured when turning</li> </ul> </td> <td> <ul> <li>Effects of prone ventilation typically seen over 4 to 8 hours; improvements continue the longer it is used.</li> </ul> </td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Additional rescue therapies</td> <td> <ul> <li>For patients who fail prone ventilation (eg, P/F ratio &lt;150 mmHg while prone), may consider the following interventions: <ul> <li>Recruitment maneuvers and high PEEP strategies</li> <li>Trial of inhaled pulmonary vasodilators such as NO/epoprostenol</li> <li>Neuromuscular blockade for patients with refractory hypoxemia (eg, P/F ratio &lt;100 mmHg) or ventilator dyssynchrony</li> <li>ECMO as a last resort; however, ECMO is not universally available</li> </ul> </li> </ul> </td> <td> <ul> <li>Please refer to UpToDate topic text for details on how to perform recruitment maneuvers and administer higher than usual levels of PEEP.</li> <li>Pulmonary vasodilators should <strong>not</strong> be administered unless a specific protocol and staff experienced in their administration are in place. Inhaled vasodilators may increase aerosolization.</li> <li>Numerical improvement due to pulmonary vasodilators should not prevent prone positioning when otherwise indicated.</li> </ul> </td> </tr> <tr> <td class="subtitle1_left">Pharmacotherapy</td> <td class="subtitle1_left">Actions</td> <td class="subtitle1_left">Explanatory notes</td> </tr> <tr> <td class="indent1" colspan="2">Implement ICU protocols for sedation, analgesia, neuromuscular blockade (if needed), stress ulcer prophylaxis, thromboembolism prophylaxis, glucose control</td> <td> </td> </tr> <tr> <td class="indent1">Empiric antibiotics</td> <td> <ul> <li>For suspected bacterial coinfection (eg, elevated WBC, positive sputum culture, positive urinary antigen, atypical chest imaging), administer empiric coverage for community-acquired or healthcare-associated pneumonia</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">COVID-19-specific therapy</td> <td> <ul> <li>COVID-19-specific therapy, including dexamethasone, remdesivir, and interleukin-6 inhibitors should be considered. Therapies are evolving.</li> </ul> </td> <td> <ul> <li>Refer to other UpToDate content for details.</li> </ul> </td> </tr> <tr class="border_bottom_thick"> <td class="indent1">Glucocorticoids for non-COVID-19 illnesses</td> <td> <ul> <li>Give glucocorticoids for other indications (eg, asthma, COPD)</li> </ul> </td> <td> <ul> <li>Refer to other UpToDate content for details.</li> </ul> </td> </tr> <tr> <td class="subtitle1_left">Adjustments to outpatient meds</td> <td class="subtitle1_left">Actions</td> <td class="subtitle1_left">Explanatory notes</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Assess and seek expert consultation to manage comorbid conditions (asthma, COPD, sickle cell disease, immunocompromise, pregnancy)</strong></td> <td> </td> </tr> <tr> <td class="indent1">ICS</td> <td> <ul> <li>For asthma, continue usual dose</li> <li>For COPD <strong>without</strong> asthmatic component or clear prior benefit, hold ICS</li> <li>For COPD <strong>with</strong> asthmatic component or clear prior benefit, continue ICS</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">NSAIDs</td> <td> <ul> <li>Acetaminophen is preferred antipyretic</li> </ul> </td> <td> <ul> <li>There are minimal data informing the risks of NSAIDs in the setting of COVID-19. Given the uncertainty, we use acetaminophen as the preferred antipyretic agent.</li> </ul> </td> </tr> <tr> <td class="indent1">ACEi/ARBs</td> <td> <ul> <li>Continue if there is no other reason for discontinuation (eg, hypotension, acute kidney injury)</li> </ul> </td> <td> </td> </tr> <tr> <td class="indent1">Statins</td> <td> <ul> <li>Patients taking a statin at baseline should continue</li> </ul> </td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ICU: intensive care unit; COVID-19: coronavirus disease 2019; CDC: Centers for Disease Control and Prevention; WHO: World Health Organization; BAL: bronchoalveolar lavage; CRS: cytokine release syndrome; CRP: C-reactive protein; LDH: lactate dehydrogenase; LFTs: liver function tests; CBC: complete blood count; BNP: brain natriuretic peptide; CPK: creatinine phosphokinase; POC: point of care; CT: computed tomography; ECG: electrocardiogram; QTc: rate-corrected QT interval; ARDS: acute respiratory distress syndrome; ABGs: arterial blood gasses; IV: intravenous; MDIs: metered dose inhalers; COPD: chronic obstructive pulmonary disease; SpO<sub>2</sub>: pulse oxygen saturation; NC: nasal cannula; NRB: nonrebreather; HFNC: high flow nasal cannula; NIV: noninvasive ventilation; ACHF: acute congestive heart failure; FiO<sub>2</sub>: fraction of inspired oxygen; TV: tidal volume; AC: assist controlled; IBW: ideal predicted body weight; PEEP: positive end-expiratory pressure; PaO<sub>2</sub>: arterial oxygen tension; P/F ratio: PaO<sub>2</sub>/FiO<sub>2</sub>; ETT: endotracheal tube; NO: nitric oxide; ECMO: extracorporeal membrane oxygenation; WBC: white blood count; ICS: inhaled corticosteroids; NSAIDs: nonsteroidal anti-inflammatory agents; ACEi: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor blockers.</p>
<p>* The CDC and WHO note that a medical/surgical mask is an alternative in the absence of aerosol generating procedures if N95 mask is not available.</p>
¶ Evidence suggests that a subgroup of patients with severe COVID-19 may be eligible for immune suppression with tocilizumab in the setting of a trial or compassionate use. The rationale is that COVID-19 may have CRS or a CRS-like presentation as suggested by organ failure, increasing ferritin, CRP, LDH, erythrocyte sedimentation rate, thrombocytopenia, and lymphopenia. Administration of tocilizumab warrants discussion with a subspecialist and eligible patients may need an interleukin-6 level measured. Troponins may be measured daily or as indicated if cardiac dysfunction is suspected. Triglycerides should be measured when patients are on propofol for sedation. Marker of disseminated intravascular coagulopathy including activated partial thromboplastin, activated thrombin, D-dimer, and fibrinogen are also regularly monitored as are LFTs and a complete blood count and differential.</div><div class="graphic_reference">References:
<ol>
<li>FACTT Algorithm: Composite Protocol-Version 2. Available at: <a href="http://www.ardsnet.org/files/factt_algorithm_v2.pdf" target="_blank">http://www.ardsnet.org/files/factt_algorithm_v2.pdf</a> (Accessed on April 1, 2020).</li>
<li>Barrot L, Asfar P, Mauny F, et al. Liberal or Conservative Oxygen Therapy for Acute Respiratory Distress Syndrome. N Engl J Med 2020; 382:999.</li>
<li>Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med 2013; 368:2159.</li>
<li>Sickle Cell Disease and COVID-19: An Outline to Decrease Burden and Minimize Morbidity. Available at: <a href="https://www.sicklecelldisease.org/2020/03/18/sickle-cell-disease-and-covid-19-provider-directory/" target="_blank">https://www.sicklecelldisease.org/2020/03/18/sickle-cell-disease-and-covid-19-provider-directory/</a> (Accessed on December 13, 2021).</li>
<li>Breastfeeding and caring for newborns if you have COVID-19. Centers for Disease Control and Prevention. Available at: <a href="https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/pregnancy-breastfeeding.html" target="_blank">https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/pregnancy-breastfeeding.html</a> (Accessed on December 15, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 127595 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
